PHVS

Pharvaris N.V.

• TipRanks·3d ago

  Pharvaris announces publication of review article on bradykinin

• Benzinga·3d ago

  Pharvaris Announces Publication Of Comprehensive Review On Bradykinin Biology And B2R Antagonism In Clinical Reviews In Allergy & Immunology

• Simply Wall St·5d ago

  Pharvaris (PHVS) Could Be 92% Undervalued On FDA NDA Acceptance

• Seeking Alpha·6d ago

  Oppenheimer’s ‘best of the best’ momentum list: NVDA, LRCX and more

• Simply Wall St·07/16 12:30

  Did FDA’s NDA Acceptance for Deucrictibant Just Shift Pharvaris' (PHVS) Hereditary Angioedema Narrative?

• TipRanks·07/15 13:35

  IBM downgraded, Cava upgraded: Wall Street’s top analyst calls

• Dow Jones·07/15 11:12

  Pharvaris Price Target Announced at $55.00/Share by Wells Fargo

• Benzinga·07/15 11:03

  Wells Fargo Initiates Coverage On Pharvaris with Overweight Rating, Announces Price Target of $55

• TipRanks·07/15 09:35

  Pharvaris initiated with an Overweight at Wells Fargo

• Simply Wall St·07/08 15:40

  How Investors May Respond To Pharvaris (PHVS) FDA Acceptance Of Deucrictibant NDA For HAE Attacks

• NASDAQ·07/06 11:59

  Pharvaris Gains FDA Acceptance For Deucrictibant In Hereditary Angioedema

• NASDAQ·07/06 11:36

  Pharvaris Says FDA Accepts Deucrictibant NDA For On-demand Treatment Of Hereditary Angioedema Attack

• Benzinga·07/06 10:53

  Pharvaris Says FDA Accepts NDA For Deucrictibant IR Capsule (20 Mg) For On-Demand Treatment Of Hereditary Angioedema Attacks; PDUFA Target Action Date Set April 23, 2027

• PUBT·07/06 10:50

  Pharvaris says FDA accepts NDA for deucrictibant in hereditary angioedema attacks

• Reuters·07/06 10:50

  PHARVARIS NV - FDA SETS PDUFA ACTION DATE FOR DEUCRICTIBANT IR NDA AS APRIL 23, 2027